On Wednesday, the World Health Organisation (WHO) gave the Oxford/Astrazeneca COVID-19 vaccine emergency use validation making it the second vaccine candidate to be approved after the Pfizer BioNtech last month. Both vaccines are not recommended for use by pregnant and l
The National Institute of Health is calling upon researchers to
involve pregnant mothers while studying COVID-19 vaccines. This follows a just-published
study by the Institute that shows pregnant people are at increased risk of
hospitalization and have a 3-fold adjusted relative risk of needing intensive
care and mechanical ventilation compared with age-matched non-pregnant
According to Dr Diana Bianchi, the Director of the National Institute of Child
Health and Human Development at NIH, manufacturers of all the currently
available vaccines that have so far been administered to people in ten
countries across the globe excluded pregnant and lactating women from clinical
trials putting clinicians and pregnant women in a tricky situation to make
real-time decisions now about the vaccine based on little or no scientific
evidence that applies specifically to them.
On Wednesday, the World Health Organisation (WHO) gave the
Oxford/Astrazeneca COVID-19 vaccine emergency use validation making it the
second vaccine candidate to be approved after the Pfizer BioNtech last
month. Both vaccines are not recommended for use by pregnant and lactating
“Pregnant women are not supposed to be vaccinated if it can be
avoided since the risk the vaccine presents to expectant mothers is unknown”,
read in part the recommendations by the WHO Scientific Advisory Group on
Emergencies (SAGE) yesterday as they approved the use of AstraZeneca.
Bainchi says that this conflicting information being provided to
pregnant individuals stems from long-standing obstacles to the inclusion of
pregnant and lactating people in clinical research.
“The data provided by the manufacturers in the Emergency Use
Authorizations for both the Pfizer and Moderna vaccines described the specific
exclusion of pregnant people. Those who became pregnant during the trials
provided very limited data to inform evidence of safety and effectiveness in
She warns in a press release that the continued exclusion of this
key group in scientific research is risky since pregnant people need to be
protected through research rather than from research.
However, research shows pregnant people with laboratory-confirmed
severe or critical COVID-19 disease have a higher risk of caesarean delivery,
excessive bleeding after delivery also called postpartum haemorrhage,
hypertensive disorders of pregnancy and preterm birth.